Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 6/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083583 | 0.89 | MAPK14 (0.60) | KLKB1TRPV1MAPK14RAF1BRAF | |
| SCHEMBL2083826 | 0.84 | KLKB1 (0.51) | KLKB1TRPV1CARM1 | |
| SCHEMBL14659672 | 0.77 | TRPV1 (0.51) | KLKB1TRPV1 | |
| SCHEMBL2084851 | 0.75 | MAPK14 (0.47) | KLKB1MAPK14RAF1BRAFEPHB2 | |
| SCHEMBL17064574 | 0.75 | KLKB1 (0.82) | KLKB1CARM1 | |
| SCHEMBL2081647 | 0.75 | NPC1 (0.61) | MAPK14RAF1BRAFEPHB2 | |
| SCHEMBL1012734 | 0.75 | PTGS1 (0.63) | KLKB1 | |
| SCHEMBL5474058 | 0.74 | CARM1 (0.61) | MAPK14CARM1 | |
| SCHEMBL1013431 | 0.74 | ALDH1A1 (0.65) | KLKB1TRPV1MAPK14 | |
| SCHEMBL4051322 | 0.74 | KLKB1 (0.49) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | KLKB1 1841/4885TRPV1 2872/4885MAPK14 128/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KLKB1 2065/4885TRPV1 2537/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.